Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposureReportar como inadecuado




Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Virology Journal

, 10:277

Hepatitis viruses

Abstract

AimsMajority of previous studies of pegylated interferon α-2a PegIFNα-2a forced on naïve chronic hepatitis B CHB patients, and the data of PegIFNα-2a in therapy of patients with prior exposure to nucleostide analogues is rare. This study aimed to investigate the predictive role of serum quantitative hepatitis B surface antigen HBsAg in predicting sustained response of PegIFNα-2a in HBeAg-positive CHB patients with prior lamivudine exposure.

MethodsForty-six patients with prior lamivudine exposure received PegIFNα-2a for 12 months and followed-up for 6 months. The clinical features of responders and non-responders were compared, and the predictive role of quantitative HBsAg in predicting responders at the end of follow-up was evaluated. Responders were defined as an ALT normalization, HBeAg seroconversion and sustained virological response at the end of follow-up.

ResultsIn this cohort, only 26.1% 12-46 patients were responders. The baseline characteristics of the responders and non-responders were similar; however, the rates of ALT normalization, HBV DNA undetectability and HBeAg seroconversion were all significantly higher in responders than that in non-responders. During the treatment and follow-up, the HBsAg levels were all significantly lower in responders than that in non-responders. In predicting reponders, the serum HBsAg cutoff of 6000 IU-mL at months 6 had a positive predictive value of 73.3 and a negative predictive value of 96.8%, and with an area under the receiver operating characteristic curve of 0.869.

ConclusionThe responders toward PegIFNα-2a in CHB patients with prior lamivudine exposure is not high, and serum HBsAg <6000 IU-Ml at months 6 of on-treatment had a high value to predict long-term outcomes of treatment.

KeywordsChronic hepatitis B Lamivudine exposure Pegylated interferon α-2a Hepatitis B surface antigen quantification Predictability  Download fulltext PDF



Autor: Min Weng - Wei-Zheng Zeng - Xiao-Ling Wu - Yong Zhang - Ming-De Jiang - Zhao Wang - De-Jiang Zhou - Xuan He

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados